Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.
Horn
Michael P
MP
Kenta Biotech AG, Rehhagstrasse 79, CH-3018 Bern, Switzerland. michael.rudolf@kentabiotech.com
Zuercher
Adrian W
AW
Imboden
Martin A
MA
Rudolf
Michael P
MP
Lazar
Hedvika
H
Wu
Hong
H
Hoiby
Niels
N
Fas
Stefanie C
SC
Lang
Alois B
AB
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology* / Q000627:therapeutic use / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use / Q000633:toxicity; D000915:Antibody Affinity; D000918:Antibody Specificity; D001483:Base Sequence; D002460:Cell Line; D003165:Complement System Proteins / Q000378:metabolism; D017931:DNA Primers / Q000235:genetics; D004195:Disease Models, Animal; D018922:HL-60 Cells; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology* / Q000627:therapeutic use / Q000633:toxicity; D066298:In Vitro Techniques; D051379:Mice; D010587:Phagocytosis; D018410:Pneumonia, Bacterial / Q000276:immunology / Q000517:prevention & control; D011552:Pseudomonas Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D011550:Pseudomonas aeruginosa / Q000145:classification / Q000235:genetics / Q000276:immunology*; D011817:Rabbits; D018805:Sepsis / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D012703:Serotyping
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D017931:DNA Primers; D007075:Immunoglobulin M; D003165:Complement System Proteins